Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sickle Cell Pain Clear all
Completed Phase 3 Interventional Results available

Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally

NCT01380197
View directory record Official record
Conditions
Pain, Sickle Cell Disease
Interventions
Morphine, Nubain
Drug
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
6 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 23, 2026, 8:06 PM EDT
Suspended Not applicable Interventional

Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults With Sickle Cell Disease (SCD)

NCT05457790
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia, Insomnia, Sleeplessness, Transient Insomnia, Nonorganic Insomnia, Chronic Insomnia
Interventions
ACT Intervention, Waitlist
Behavioral
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 23, 2026, 8:06 PM EDT
Withdrawn Phase 2 Interventional

Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlusive Crisis (VOC)

NCT00711698
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Patient controlled analgesia, nurse-administered intermittent IV bolus opioid therapy (NAIBOD)
Procedure · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Not applicable Interventional

Laboratory-based Hypnosis Intervention on Pain Responsivity in Adolescents With Sickle Cell Disease

NCT02987725
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Hypnosis, Attention Control
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Years to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism

NCT03938454
View directory record Official record
Conditions
Priapism
Interventions
Crizanlizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Farmington, Connecticut • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 23, 2026, 8:06 PM EDT
Terminated No phase listed Observational

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products

NCT03886753
View directory record Official record
Conditions
ALS, Autism Spectrum Disorder, Cancer, Spasticity, Muscle, Dyskinetic Syndrome, Epilepsy, Glaucoma, Huntington Disease, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Neuropathy, Opioid Use, Parkinson Disease, HIV/AIDS, Ptsd, Intractable Pain, Sickle Cell Disease, Terminal Illness
Interventions
Registry, PK microsampling of blood
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Not applicable Interventional

Sickle Cell, Pain and Mediterranean Diet

NCT06886477
View directory record Official record
Conditions
Sickle Cell, Sickle Cell Disease, Sickle Cell Disease Without Crisis, Mediterranean Diet
Interventions
Mediterranean Diet, Usual Diet
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 23, 2026, 8:06 PM EDT
Active, not recruiting Not applicable Interventional

Study on Use of Omega-3 Fatty Acids to Improve Outcomes in Individuals With Sickle Cell Disease

NCT05758766
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Plant-based omega-3-FA
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
5 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease

NCT01702246
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Simvastatin
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
10 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2016 · Synced Sep 23, 2026, 8:06 PM EDT
Completed No phase listed Observational

Pain Management Protocol for Pediatric Sickle Cell Disease

NCT00386048
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Brief Cognitive-Behavioral Pain Management Training
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
8 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Phase 2 Interventional

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

NCT00236093
View directory record Official record
Conditions
Pain, Cancer, Sickle Cell Anemia, Severe Burns
Interventions
ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])
Drug
Lead sponsor
Cephalon
Industry
Eligibility
3 Years to 15 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
26
States / cities
Little Rock, Arkansas • Orange, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Phase 1Phase 2 Interventional

Codeine in Sickle Cell Disease

NCT00174538
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Codeine (30 mg)
Drug
Lead sponsor
PriCara, Unit of Ortho-McNeil, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Sep 23, 2026, 8:06 PM EDT
Terminated Phase 3 Interventional

Intranasal Ketamine for Pain Control in Patients with Sickle Cell Disease and Vaso-occlusive Episode (VOE) in the PED

NCT04150757
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis, Ketamine, Intranasal Ketamine, Analgesia
Interventions
Intranasal ketamine
Drug
Lead sponsor
Abigail Nixon
Other
Eligibility
3 Years to 25 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Phase 2 Interventional Results available

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease

NCT01476696
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Prasugrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Oakland, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Sep 23, 2026, 8:06 PM EDT
Recruiting Not applicable Interventional

Trans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease

NCT07090668
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
tAN device
Device
Lead sponsor
Emory University
Other
Eligibility
7 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Phase 1 Interventional

Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease

NCT00095472
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
L-NMMA, Sodium Nitrite
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Sep 23, 2026, 8:06 PM EDT
Completed No phase listed Observational

Living With Sickle Cell Disease in the COVID-19 Pandemic

NCT04417673
View directory record Official record
Conditions
Isolation, Anxiety, Health Care Utilization, Sickle Cell Disease, Pain
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Not applicable Interventional

Distracting Through Procedural Pain and Distress

NCT04892160
View directory record Official record
Conditions
Chronic Illness, Hematologic Malignancy, Bone Marrow Transplant Infection, Oncology, Sickle Cell Disease
Interventions
Guided Imagery, Virtual Reality
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
8 Years to 25 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Milwaukee, Wisconsin • Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 23, 2026, 8:06 PM EDT
Active, not recruiting Not applicable Interventional

Integrative Medicine in Pain Management in Sickle Cell Disease

NCT05045820
View directory record Official record
Conditions
Sickle Cell Disease, Pain, Acupuncture, Quantitative Sensory Testing, Magnetic Resonance Imaging, Circulating Biomarkers, Electroencephalography, Functional Near-infrared Spectroscopy
Interventions
needling acupuncture, laser acupuncture
Device
Lead sponsor
Indiana University
Other
Eligibility
14 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 23, 2026, 8:06 PM EDT
Terminated Phase 3 Interventional

THE IMPROVE TRIAL: Improving Pain Management and Outcomes With Various Strategies of Patient-Controlled Analgesia (PCA)

NCT00999245
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
High Demand / Low Infusion, PCA Dosing Plan
Other
Lead sponsor
Carelon Research
Other
Eligibility
10 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
28
States / cities
Oakland, California • New Haven, Connecticut • Wilmington, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Sep 23, 2026, 8:06 PM EDT
Not yet recruiting Phase 1 Interventional

Buprenorphine for the Management of Pain in Children With Sickle Cell Disease

NCT07799571
View directory record Official record
Conditions
Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Sickle Cell Hemoglobin C Disease, Pain Crisis
Interventions
Buprenorphine Buccal Film [Belbuca]
Drug
Lead sponsor
Natasha Archer
Other
Eligibility
12 Years to 22 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Not applicable Interventional Results available

Effectiveness of a Computerized Tool (PAINRelieveIt) to Help Manage Pain Related to Sickle Cell Disease

NCT00600665
View directory record Official record
Conditions
Anemia, Sickle Cell, Hemoglobin SC Disease
Interventions
PAINReportIt (Phase 1 + 2), PAINUCope (Phase 1), PAINConsultN (Phase 2), PAINUCope (Phase 2)
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Early Phase 1 Interventional Results available

A Dose-Finding Study of AG-348 in Sickle Cell Disease

NCT04000165
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
AG-348
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Sep 23, 2026, 8:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease

NCT04584528
View directory record Official record
Conditions
Sickle Cell Disease, Genetic Disease, Hematologic Diseases, Anemia, Sickle Cell
Interventions
Electronic Health Record (EHR) Embedded Individualized Pain Plan (IPP)
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years
Enrollment
279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
8
States / cities
Oakland, California • Augusta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Sep 23, 2026, 8:06 PM EDT